ARDX insider Rodgers gets equity grants worth 63k shares in Form 4
Rhea-AI Filing Summary
Ardelyx, Inc. (ARDX) – Form 4 insider transaction filed 06/23/2025
Board member Richard J. Rodgers reported routine, compensation-related equity grants dated 06/18/2025 under Ardelyx’s Non-Employee Director Compensation Program:
- 21,468 common shares issued in lieu of cash fees, increasing his direct holdings to 371,992 shares.
- 41,551 restricted stock units (RSUs); each RSU converts 1-for-1 to common stock as it vests, bringing total directly held shares to 413,543 on a fully delivered basis.
- 54,059 stock options with a $3.61 exercise price, 10-year term (expiring 06/18/2035). Vesting is 1/12 monthly with full acceleration at the next annual meeting if service continues.
No sales were reported and all awards were granted at $0 cost to the director. Transactions reflect standard annual director compensation and represent a small, immaterial dilution to existing shareholders.
Positive
- Director retains and increases equity stake, reinforcing alignment with shareholder interests
- Cashes conserved by issuing stock instead of cash compensation
Negative
- Minor dilution to existing shareholders from new share issuance
Insights
TL;DR: Routine director equity grants; minimal dilution, neutral impact.
The filing documents annual compensation equity for director Richard J. Rodgers—21.5 k shares, 41.6 k RSUs, and 54.1 k options at $3.61. Post-grant direct ownership rises to 413.5 k shares, signaling continued alignment but not insider buying with out-of-pocket cash. The volume is immaterial versus Ardelyx’s ~235 m shares outstanding (<0.03% dilution). Options are slightly out-of-the-money versus recent ~$4 price, providing incentive if shares appreciate. For investors, the disclosure is compliance-oriented with no read-through to fundamentals or near-term price direction.
TL;DR: Standard board compensation, signals alignment; governance posture intact.
The company grants equity instead of cash, enhancing director-shareholder alignment while conserving cash. Monthly vesting plus acceleration at the next AGM is typical for small-cap biotech boards, balancing retention with flexibility. No red flags in structure, pricing, or timing; the 10b5-1 checkbox was not marked, indicating discretionary issuance rather than a pre-arranged trade. Overall governance neutral, supporting best-practice transparency.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 54,059 | $0.00 | -- |
| Grant/Award | Common Stock | 21,468 | $0.00 | -- |
| Grant/Award | Common Stock | 41,551 | $0.00 | -- |
Footnotes (1)
- The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
